Mary Gerritsen Consulting and Editing

YOLARX is world-renown for its scientific excellence in pharmacoepidemiology, pharmacovigilance, and therapeutic risk management. 

Since its founding in 2006, YOLARX has developed and integrated an unique approach as it spans the product life-cycle following a roadmap which corresponds to the changing environment of drug regulation and reimbursement.

Our goal is to provide expertise and research of the highest methodological standards that evaluate the benefits and risks of medicines in the real-world, for a global client base.

Therapeutic areas in which YOLARX has worked include neuro-psychiatry, cardiovascular and metabolic disease, infectious disease, hematology/oncology, immunology/inflammation, pain, ophthalmology, dermatology, pulmonary disease, vaccinology, rare disease and biosimilars, …

To learn more about YOLARX Consultants, please visit: www.yolarx.com.

Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.

Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.

Multispan, Inc. is a premier assay screening technology provider targeting GPCRs, kinases and beyond using endogenously expressed targets in primary cells and recombinant stable cell lines. It has created the industry’s largest, highly characterized, highest quality GPCR-expressing stable cell lines and assays based on cell signaling and phenotypic biology. Multispan offers integrated high quality solutions in assay development, HTS and SAR lead optimization screening support to shorten time to IND and discover better medicine in cardiovascular, metabolic, CNS, inflammation, immunology and oncology diseases. Multispan’s high standard of quality and integrity has earned successful long-term collaborations with a wide range of leading pharmaceutical and biotech companies globally.

Wickenstones is a full service market access consultancy working with the pharmaceutical, biotech, diagnostic and device sectors.

Founded with two clear objectives:
- Build strong internal alignment for our clients to maximise the value of their assets.
- Overcome the complex and difficult challenges of market access through persistence and innovation.

Our project leaders have over 150 years experience in the healthcare industry and access consulting.

Backgrounds
General management in pharma - Market access leadership across European and global organisations - Medical affairs leadership and experience in top level market access consultancies.

Therapy Areas
Experience from phase I to beyond loss of exclusivity in many therapy areas including oncology – respiratory - mental health – cardiovascular – autoimmune – ophthalmology – vaccines – virology - dermatology & wound care.

Geographical Scope
We have global reach and experience including European markets - The USA – Brazil – Russia – India - China (BRIC) plus other Asian markets.

Reach
We have affiliated staff in the UK, Scandinavia, Italy, Spain, France and Switzerland.

Quality
All our work is underwritten by our commitment to quality.

As the drug development business of Laboratory Corporation of America Holdings (Labcorp) and the world’s most comprehensive drug development #CRO service company, we have helped pharmaceutical and biotech companies develop 100% of the top 50 prescription drugs in the marketplace today.

Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality.